{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:02:47Z","timestamp":1792587767606,"version":"4.5.0"},"reference-count":40,"publisher":"FapUNIFESP (SciELO)","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Inst. Med. trop. S. Paulo"],"DOI":"10.1590\/s1678-9946202264061","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T13:39:17Z","timestamp":1664545157000},"source":"Crossref","is-referenced-by-count":3,"title":["Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A\/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis"],"prefix":"10.1590","volume":"64","author":[{"given":"Ana Paula de Torres","family":"Santos","sequence":"first","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa Cristina Martins","family":"Silva","sequence":"additional","affiliation":[{"name":"Instituto Adolfo Lutz, Centro de Virologia,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5655-8108","authenticated-orcid":false,"given":"Maria C\u00e1ssia","family":"Mendes-Corr\u00eaa","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcilio Figueiredo","family":"Lemos","sequence":"additional","affiliation":[{"name":"Instituto Adolfo Lutz, Centro de Virologia,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda de Mello","family":"Malta","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fabia Anita Ferraz","family":"Santana","sequence":"additional","affiliation":[{"name":"Hospital Israelita Albert Einstein,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg\u00f3rio Tadeu Fernando","family":"Dastoli","sequence":"additional","affiliation":[{"name":"Hospital Israelita Albert Einstein,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa Fusco Duarte de","family":"Castro","sequence":"additional","affiliation":[{"name":"Hospital Israelita Albert Einstein,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3999-0489","authenticated-orcid":false,"given":"Jo\u00e3o Renato Rebello","family":"Pinho","sequence":"additional","affiliation":[{"name":"Universidade de S\u00e3o Paulo,  Brazil; Universidade de S\u00e3o Paulo,  Brazil; Hospital Israelita Albert Einstein,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8208-8776","authenticated-orcid":false,"given":"Regina C\u00e9lia","family":"Moreira","sequence":"additional","affiliation":[{"name":"Instituto Adolfo Lutz, Centro de Virologia,  Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2022]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S2468-1253(21)00472-6","article-title":"Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study","volume":"7","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/infdis\/jiy401","article-title":"Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes","volume":"218","author":"Borgia SM","year":"2018","journal-title":"J Infect Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1590\/S0100-879X2005000100007","article-title":"Geographic distribution of hepatitis C virus genotypes in Brazil","volume":"38","author":"Campiotto S","year":"2005","journal-title":"Braz J Med Biol Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s13337-021-00697-0","article-title":"Current therapeutics against HCV","volume":"32","author":"Bhattacharjee C","year":"2021","journal-title":"Virusdisease"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/jvh.13270","article-title":"Prevalence of HCV resistance-associated substitutions among treatment-failure patients receiving direct-acting antiviral agents","volume":"27","author":"Liu Z","year":"2020","journal-title":"J Viral Hepat"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"6573","DOI":"10.3748\/wjg.v22.i29.6573","article-title":"Treatment of chronic hepatitis C with direct-acting antivirals: the role of resistance","volume":"22","author":"Jim\u00e9nez-P\u00e9rez M","year":"2016","journal-title":"World J Gastroenterol"},{"key":"ref7","series-title":"Protocolo cl\u00ednico e diretrizes terap\u00eauticas para hepatite C e coinfec\u00e7\u00f5es","year":"2015"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster GR","year":"2016","journal-title":"J Hepatol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00705-022-05375-0","article-title":"Progress, evolving therapeutic\/diagnostic approaches, and challenges in the management of hepatitis C virus infections","volume":"167","author":"Meshram RJ","year":"2022","journal-title":"Arch Virol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijid.2020.03.061","article-title":"NS5A resistance-associated substitutions in chronic hepatitis C patients with direct acting antiviral treatment failure in Turkey","volume":"95","author":"Sayan M","year":"2020","journal-title":"Int J Infect Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00705-016-3094-2","article-title":"Natural occurrence of NS5B inhibitor resistance-associated variants in Brazilian patients infected with HCV or HCV and HIV","volume":"162","author":"Noble CF","year":"2017","journal-title":"Arch Virol"},{"key":"ref12","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-017-2817-7","article-title":"Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil","volume":"17","author":"Malta F","year":"2017","journal-title":"BMC Infect Dis"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e0179562","DOI":"10.1371\/journal.pone.0179562","article-title":"An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains","volume":"12","author":"Andre-Garnier E","year":"2017","journal-title":"PloS One"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"723","DOI":"10.2147\/IDR.S247071","article-title":"Prevalence and pattern of resistance in NS5A\/NS5B in hepatitis C chronic patients genotype 3 examined at a public health laboratory in the State of S\u00e3o Paulo, Brazil","volume":"14","author":"Santos AP","year":"2021","journal-title":"Infect Drug Resist"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0166-0934(03)00070-3","article-title":"Determining hepatitis C genotype by analyzing the sequence of the NS5b region","volume":"109","author":"Sandres-Saun\u00e9 K","year":"2003","journal-title":"J Virol Methods"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1073\/pnas.74.12.5463","article-title":"DNA sequencing with chain-terminating inhibitors","volume":"74","author":"Sanger F","year":"1977","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"e0155869","DOI":"10.1371\/journal.pone.0155869","article-title":"Geno2pheno[HCV]: a web-based interpretation system to support hepatitis C treatment decisions in the era of direct-acting antiviral agents","volume":"11","author":"Kalaghatgi P","year":"2016","journal-title":"PLoS One"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"543","DOI":"10.4254\/wjh.v10.i9.543","article-title":"Hepatitis C resistance to NS5A inhibitors: is it going to be a problem?","volume":"10","author":"Sharafi H","year":"2018","journal-title":"World J Hepatol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jhep.2015.09.011","article-title":"The importance of resistance to direct antiviral drugs in HCV infection in clinical practice","volume":"64","author":"Sarrazin C","year":"2016","journal-title":"J Hepatol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower E","year":"2014","journal-title":"J Hepatol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.drup.2018.01.004","article-title":"Hepatitis C virus drug resistance associated substitutions and their clinical relevance","volume":"37","author":"Sorbo MC","year":"2018","journal-title":"Drug Resist Updat"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/hep.20819","article-title":"Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes","volume":"42","author":"Simmonds P","year":"2005","journal-title":"Hepatology"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1469-0691.2010.03432.x","article-title":"Evolving epidemiology of hepatitis C virus","volume":"17","author":"Lavanchy D","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jcv.2012.04.024","article-title":"Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b","volume":"54","author":"Suzuki F","year":"2012","journal-title":"J Clin Virol"},{"key":"ref25","first-page":"1185","article-title":"Current recommendations for the treatment of chronic hepatitis C","volume":"52","author":"Sarrazin C","year":"2014","journal-title":"Z Gastroenterol"},{"key":"ref26","first-page":"255","article-title":"Efficacy and safety of all-oral Emitasvir and Sofosbuvir in patients with genotype 1b HCV infections without cirrhosis","volume":"8","author":"Rao H","year":"2020","journal-title":"J Clin Transl Hepatol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3390\/v11010003","article-title":"Prevalence and factors related to natural resistance-associated substitutions to direct-acting antivirals in patients with genotype 1 hepatitis C virus infection","volume":"11","author":"Esposito I","year":"2018","journal-title":"Viruses"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.02524-15","article-title":"In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir","volume":"60","author":"Cheng G","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/rmv.1895","article-title":"Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time","volume":"26","author":"Cuypers L","year":"2016","journal-title":"Rev Med Virol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1053\/j.gastro.2017.12.015","article-title":"Efficacy of NS5A inhibitors against hepatitis C virus genotypes 1-7 and escape variants","volume":"154","author":"Gottwein JM","year":"2018","journal-title":"Gastroenterology"},{"key":"ref31","first-page":"103","article-title":"Understanding hepatitis C virus drug resistance: clinical implications for current and future regimens","volume":"25","author":"Wyles DL","year":"2017","journal-title":"Top Antivir Med"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"e0216327","DOI":"10.1371\/journal.pone.0216327","article-title":"Treatment of chronic HCV infection with DAAs in Rio de Janeiro\/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes","volume":"14","author":"Costa VD","year":"2019","journal-title":"PLoS One"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s15010-018-1188-3","article-title":"Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure","volume":"46","author":"Sagnelli E","year":"2018","journal-title":"Infection"},{"key":"ref34","doi-asserted-by":"crossref","DOI":"10.1038\/srep41719","article-title":"Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment","volume":"7","author":"Eltahla AA","year":"2017","journal-title":"Sci Rep"},{"key":"ref35","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2514901","article-title":"Pretreatment hepatitis C virus NS5A\/NS5B resistance-associated substitutions in genotype 1 Uruguayan infected patients","volume":"2018","author":"Aldunate F","year":"2018","journal-title":"Dis Markers"},{"key":"ref36","first-page":"12","article-title":"Resistance associated mutations in HCV patients failing DAA treatment","volume":"44","author":"Di Stefano M","year":"2021","journal-title":"New Microbiol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1111\/liv.14797","article-title":"Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C","volume":"41","author":"Di Maio VC","year":"2021","journal-title":"Liver Int"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1111\/liv.14849","article-title":"Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: a real-world nationwide hepatitis C virus registry programme in Taiwan","volume":"41","author":"Chen CY","year":"2021","journal-title":"Liver Int"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/jac\/dku462","article-title":"NS5A inhibitor resistance-associated polymorphisms in Brazilian treatment-naive patients infected with genotype 1 hepatitis C virus","volume":"70","author":"Peres-da-Silva A","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.clinre.2019.07.015","article-title":"Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil","volume":"44","author":"Aguiar BF","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"}],"container-title":["Revista do Instituto de Medicina Tropical de S\u00e3o Paulo"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_pdf&pid=S0036-46652022000100233&tlng=en","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T13:40:11Z","timestamp":1664545211000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0036-46652022000100233&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":40,"alternative-id":["S0036-46652022000100233"],"URL":"https:\/\/doi.org\/10.1590\/s1678-9946202264061","relation":{},"ISSN":["1678-9946"],"issn-type":[{"value":"1678-9946","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"e61"}}